Frito Lay's Classic Potato Chips: Recall raised to highest risk level by FDA. What to know
The Food and Drug Administration just raised the recall level of Lay’s Classic Potato Chips to the highest risk classification. Frito Lay issued a recall on Dec. 16 through the FDA for over 6,000 bags ...
CNET1h
Red Dye No. 3 Can be Found in These 9 Foods in Your Pantry
After the Red No. 3 ban, there are now eight color additives approved by the FDA. They are FD&C Blue No. 1, FD&C Blue No. 2, ...
Sunscreen Recalled Nationwide as FDA Sets Risk Level
A voluntary recall was initiated by The W.S. Badger Company due to missing labels on a sunscreen product distributed ...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
5 takeaways from RFK Jr.’s first confirmation hearing as Trump’s nominee for health secretary
Robert F. Kennedy Jr. was pressed to clarify his views on vaccines, abortion, and public health priorities in his first ...
WPLG1h
Certain Lay’s potato chips considered ‘high risk’ according to FDA recall
The U.S. Food & Drug Administration has recalled a popular brand of potato chips saying the product may be high risk for some ...
Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point
Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why I rate DERM stock a Buy.
The American Journal of Managed Care2h
FDA-Approved IV Iron Formulations
Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and ...
MLive2h
Lay’s potato chip recall now elevated to FDA’s highest-risk level
The FDA has upgraded a recall of Lay’s Potato Chips to the highest level possible, meaning consuming the chips will cause ...
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.
FierceBiotech3h
Takeda axes failed epilepsy asset after FDA weighs in on data package
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...